Breast cancer is the most common malignant neoplasm affecting women worldwide, comprising 25.4% of all new cancers diagnosed in 2018.
1 Death rates from breast cancer have decreased considerably over time owing to refinement in treatment regimens, including the use of adjuvant chemotherapy and endocrine therapy.
2 However, adverse effects are significant, with hair loss affecting up to 65% of patients receiving classic chemotherapy regimens
3; 58% of patients receiving chemotherapy consider hair loss to be the most troubling adverse event, with 8% reporting they would decline treatment because of this adverse effect.
3